Andrea Apolo, M.D. (@apolo_andrea) ranks #15 among US gu cancer KOLs on X in 2026, by engagement from fellow physicians. 45 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: IMvigor011, SunRISe-2, NIAGARA. CMS Open Payments lists $198 in 2025 general payments.
At a Glance
- 3 posts naming a trial in 2026
- 3 trials discussed by name
- GU Cancer: US #15 · 45 physicians engaged
- Leading physician voice: #1 of 5 physicians on SunRISe-2; #3 of 20 physicians on IMvigor011
- Presented at ASCO 2026 in 2026
- CMS Open Payments lists $198 in 2025 general payments.
This Month
What Andrea Apolo, M.D. has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Who Amplifies Andrea Apolo, M.D.
Physicians who reposted Andrea Apolo, M.D.’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| GU Cancer | #15 | — | 45 | 56 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Andrea Apolo, M.D. presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ASCO 2026 · PresentationNectin-4 ADCs: The Past, Present, and FutureSource: @DrChoueiri on X ↗
What Colleagues Are Saying About Andrea Apolo, M.D.
2026 posts by fellow physicians that mention @apolo_andrea, quoted word for word.
Many thanks to the @OncBrothers for allowing me to be a part of yet another terrific program at #ASCO26! Was thrilled to see my @cityofhope colleague @hoperugo after my panel w @TiansterZhang & @apolo_andrea. Bonus: Got to see the incredible @jhaveri_komal just before she graced the stage!
Nectin-4 ADCs: The Past, Present, and Future: @apolo_andrea gives a sharp, elegant overview of where the field is heading: perioperative MIBC, durable 1L EV+pembro survival, and post-EV nectin-4 targeting. #ASCO26 #BladderCancer @OncoAlert @ASCO @OncBrothers https://t.co/gfgJL8nDnn
Looking forward to joining the @OncBrothers & dear friends @apolo_andrea @montypal for this #ASCO26 adjacent discussion on Sat evening! https://t.co/DxLNicgAfJ
Outstanding discussion by @apolo_andrea of the past, present & future of nectin-4 ADCs in UC #ASCO26 From EV-302 establishing EV+pembro as a transformative 1L therapy in mUC to a growing pipeline of next-generation Nectin-4 ADCs, the field continues to move rapidly. Key unanswered Qs remain: • Dose optimization • Treatment duration • Sequencing strategies • Mechanisms of resistance @tompowles1 @IyerGopa @ASCO
Trials Andrea Apolo, M.D. Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| IMvigor011 | 1 | #3 of 20 | May 15, 2026 |
| SunRISe-2 | 1 | #1 of 5 | Feb 28, 2026 |
| NIAGARA | 1 | #9 of 32 | Feb 28, 2026 |
Andrea Apolo, M.D. on IMvigor011
US FDA Approves #atezolizumab for Adjuvant Muscle-Invasive Bladder Cancer With #ctDNA-Guided Treatment based on data from #IMvigor011. This is the first approval in #BladderCancer using ctDNA. A step forward in our field. - https://t.co/JKldo5doUN
Andrea Apolo, M.D. on SunRISe-2
@AndreaNecchi presents the final results of SUNRISE-2 with tar200+IO vs chemoRT showing no benefit of TAR200+IO compared chemoRT. Important negative study! @ASCO #GU26 https://t.co/WDxsR7HwID
Andrea Apolo, M.D. on NIAGARA
UrinaryDNA analysis from NIAGARA shows that baseline and preRC clearance is associated with EFS and durvalumab ⬆️ clearance and was associated with pCR in MIBC #BladderCancer so important to do these biomarker correlative studies. Dr. Van Der Heijden and team @ASCO #GU26 https://t.co/LVVnBRCah8
Industry Payments
CMS Open Payments · 2025 general payments
$198 across 4 payments